查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1489271

全球格林巴利症候群 (GBS) 市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Guillain-Barre Syndrome (GBS) Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 224 Pages | 商品交期: 最快1-2個工作天內

價格

全球格林巴利症候群（GBS）市場需求預計將從2023年的6.7262億美元達到2032年近10.5424億美元的市場規模，2024-2032年研究期間複合年成長率為5.12%。

格林巴利症候群 (GBS) 是一種罕見的自體免疫疾病，免疫系統以周邊神經為目標，導致肌肉無力和癱瘓。症狀通常始於腿部刺痛和無力，然後可能發展到影響整個身體。感染通常會引發 GBS，需要免疫治療和物理治療等藥物治療才能康復。早期診斷和介入對於獲得更好的結果至關重要。

市場動態

格林巴利症候群 (GBS) 市場是由影響與該疾病相關的診斷、治療和研究的各種因素所驅動的。提高醫療保健專業人員和公眾對格林巴利綜合症 (GBS) 的認知有助於實現早期診斷和干涉，這對於更好的患者治療效果至關重要。 GBS 盛行率不斷上升，通常與寨卡病毒以及最近的 COVID-19 等感染有關，這加劇了人們對這種症候群的關注。醫學研究和技術進步提高了對 GBS 的了解，從而帶來更有效的治療方法。免疫球蛋白療法和血漿置換術是 GBS 的主要治療方法，已經取得了重大進展，提高了其療效和可近性。

政府和私人對罕見疾病研究的資助也透過促進創新和新的治療選擇來支持 GBS 市場的成長。此外，越來越多的專業醫療機構和先進診斷工具的出現有助於改善 GBS 的管理。醫療保健提供者、研究人員和患者權益團體之間的合作對於提高人們的認知和支持格林巴利症候群 (GBS) 患者、推動市場成長至關重要。然而，某些地區的認知有限和診斷較晚可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對格林-巴利症候群（GBS）全球市場的各個細分市場進行了包容性評估。格林巴利症候群 (GBS) 產業的成長和趨勢為本研究提供了整體方法。

市場區隔

格林-巴利綜合症 (GBS) 市場報告的這一部分提供了有關國家和區域級別細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按治療類型

  • 第一線治療（靜脈注射免疫球蛋白 (IVIG)、血漿置換（血漿置換））
  • 支持治療

按類型

  • 急性發炎性脫髓鞘多發性神經病變 (AIDP)
  • 慢性發炎性脫髓鞘多發性神經根神經病變 (CIDP)
  • 米勒費希爾症候群 (MFS)
  • 急性運動軸突神經病變 (AMAN)
  • 其他類型

按性別

  • 男性
  • 女性

按年齡段

  • 20歲以下
  • 21-40歲
  • 41-59歲
  • 60歲以上

按最終用戶

  • 醫院
  • 診所
  • 復健中心
  • 其他最終用戶

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲地區格林巴利綜合症 (GBS) 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。格林-巴利綜合症(GBS) 市場的主要參與者包括艾伯維公司(AbbVie Inc.)、百健公司(Biogen Inc.)、卡迪拉醫療保健有限公司(Cadila Healthcare Limited)、CSL Behring LLC 、F.Hoffmann-La Roche Ltd.、葛蘭素史克公司(GSK Plc)、Grifols SA、LGM Pharmaceuticals Inc.、默克公司、Octapharma AG、輝瑞公司、武田製藥有限公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：格林巴利症候群 (GBS) - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按治療類型進行的市場吸引力分析
    • 按類型分類的市場吸引力分析
    • 按性別分類的市場吸引力分析
    • 按年齡層別分類的市場吸引力分析
    • 最終用戶的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球格林巴利症候群 (GBS) 市場分析：依治療類型

  • 按治療類型概述
  • 歷史和預測數據
  • 依治療類型分析
  • 第一線治療（靜脈注射免疫球蛋白 (IVIG)、血漿置換（血漿置換））
  • 支持治療

第 6 章：全球格林巴利症候群 (GBS) 市場分析：按類型

  • 按類型概述
  • 歷史和預測數據
  • 按類型分析
  • 急性發炎性脫髓鞘多發性神經病變 (AIDP)
  • 慢性發炎性脫髓鞘多發性神經根神經病變 (CIDP)
  • 米勒費希爾症候群 (MFS)
  • 急性運動軸突神經病變 (AMAN)
  • 其他類型

第 7 章：全球格林巴利症候群 (GBS) 市場分析：依性別

  • 按性別分類的概述
  • 歷史和預測數據
  • 按性別分析
  • 男性
  • 女性

第 8 章：全球格林巴利症候群 (GBS) 市場分析：按年齡層別分類

  • 按年齡層別概述
  • 歷史和預測數據
  • 按年齡層分析
  • 20歲以下
  • 21-40歲
  • 41-59歲
  • 60歲以上

第 9 章：全球格林巴利症候群 (GBS) 市場分析：依最終用戶分類

  • 最終用戶概述
  • 歷史和預測數據
  • 最終用戶分析
  • 醫院
  • 診所
  • 復健中心
  • 其他最終用戶

第 10 章：全球格林巴利症候群 (GBS) 市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 11 章：格林巴利症候群 (GBS) 公司的競爭格局

  • 格林巴利症候群（GBS）市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 12 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • AbbVie Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Biogen Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Cadila Healthcare Limited
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • CSL Behring LLC
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • F.Hoffmann-La Roche Ltd.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • GSK Plc
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Grifols SA
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • LGM Pharmaceuticals Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Merck & Co. Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Octapharma AG
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Pfizer Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Takeda Pharmaceutical Company Limited
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR112114696

The global demand for Guillain-Barre Syndrome (GBS) Market is presumed to reach the market size of nearly USD 1054.24 Million by 2032 from USD 672.62 Million in 2023 with a CAGR of 5.12% under the study period 2024-2032.

Guillain-Barre syndrome (GBS) is an uncommon autoimmune disorder in which the immune system targets the peripheral nerves, leading to muscle weakness and paralysis. Symptoms often begin with tingling & weakness in the legs and can progress to affect the entire body. An infection typically triggers GBS and requires medical treatment such as immunotherapy and physical therapy for recovery. Early diagnosis and intervention are vital for better outcomes.

MARKET DYNAMICS

The guillain-barre syndrome (GBS) market is driven by various factors influencing the diagnosis, treatment, and research associated with this condition. Spurring awareness among healthcare professionals and the public about guillain-barre syndrome (GBS)has led to earlier diagnosis and intervention, which is crucial for better patient outcomes. The rising prevalence of GBS, often linked to infections like the Zika virus and, more recently, COVID-19, has heightened the focus on this syndrome. Medical research and technology advances have improved the understanding of GBS, leading to more effective treatments and therapies. Immunoglobulin therapy and plasmapheresis, the primary treatments for GBS, have seen significant advancements, enhancing their efficacy and accessibility.

Government and private funding for rare disease research also supports the growth of the GBS market by fostering innovation and new treatment options. Furthermore, the increasing number of specialized healthcare facilities and the availability of advanced diagnostic tools contribute to the improved management of GBS. Collaborative efforts among healthcare providers, researchers, and patient advocacy groups are vital in driving awareness and supporting those affected by guillain-barre syndrome (GBS), propelling the market growth. However, limited awareness and late diagnosis in certain regions may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Guillain-Barre Syndrome (GBS). The growth and trends of Guillain-Barre Syndrome (GBS) industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Guillain-Barre Syndrome (GBS) market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis))
  • Supportive treatment

By Type

  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Miller Fisher Syndrome (MFS)
  • Acute Motor Axonal Neuropathy (AMAN)
  • Other Types

By Gender

  • Male
  • Female

By Age Group

  • Below 20 years
  • 21-40 years
  • 41-59 years
  • 60 and above

By End-user

  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Guillain-Barre Syndrome (GBS) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Guillain-Barre Syndrome (GBS) market include AbbVie Inc., Biogen Inc., Cadila Healthcare Limited, CSL Behring LLC, F.Hoffmann-La Roche Ltd., GSK Plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. GUILLAIN-BARRE SYNDROME (GBS) - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Gender
    • 3.7.4 Market Attractiveness Analysis By Age Group
    • 3.7.5 Market Attractiveness Analysis By End-user
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Treatment Type
  • 5.4. First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Historic and Forecast Sales By Regions
  • 5.5. Supportive treatment Historic and Forecast Sales By Regions

6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TYPE

  • 6.1. Overview By Type
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Type
  • 6.4. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Historic and Forecast Sales By Regions
  • 6.5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Historic and Forecast Sales By Regions
  • 6.6. Miller Fisher Syndrome (MFS) Historic and Forecast Sales By Regions
  • 6.7. Acute Motor Axonal Neuropathy (AMAN) Historic and Forecast Sales By Regions
  • 6.8. Other Types Historic and Forecast Sales By Regions

7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GENDER

  • 7.1. Overview By Gender
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Gender
  • 7.4. Male Historic and Forecast Sales By Regions
  • 7.5. Female Historic and Forecast Sales By Regions

8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY AGE GROUP

  • 8.1. Overview By Age Group
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Age Group
  • 8.4. Below 20 years Historic and Forecast Sales By Regions
  • 8.5. 21-40 years Historic and Forecast Sales By Regions
  • 8.6. 41-59 years Historic and Forecast Sales By Regions
  • 8.7. 60 and above Historic and Forecast Sales By Regions

9. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY END-USER

  • 9.1. Overview By End-user
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By End-user
  • 9.4. Hospitals Historic and Forecast Sales By Regions
  • 9.5. Clinics Historic and Forecast Sales By Regions
  • 9.6. Rehabilitation Centers Historic and Forecast Sales By Regions
  • 9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE GUILLAIN-BARRE SYNDROME (GBS) COMPANIES

  • 11.1. Guillain-Barre Syndrome (GBS) Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. AbbVie Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Biogen Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Cadila Healthcare Limited
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. CSL Behring LLC
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. F.Hoffmann-La Roche Ltd.
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. GSK Plc
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Grifols SA
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. LGM Pharmaceuticals Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. Merck & Co. Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Octapharma AG
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. Pfizer Inc.
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Takeda Pharmaceutical Company Limited
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Market Sales By Geography (USD MN)
  • Supportive treatment Market Sales By Geography (USD MN)
  • Analysis By Type (USD MN)
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Sales By Geography (USD MN)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Sales By Geography (USD MN)
  • Miller Fisher Syndrome (MFS) Market Sales By Geography (USD MN)
  • Acute Motor Axonal Neuropathy (AMAN) Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Analysis By Gender (USD MN)
  • Male Market Sales By Geography (USD MN)
  • Female Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Below 20 years Market Sales By Geography (USD MN)
  • 21-40 years Market Sales By Geography (USD MN)
  • 41-59 years Market Sales By Geography (USD MN)
  • 60 and above Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Rehabilitation Centers Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Guillain-Barre Syndrome (GBS) Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Guillain-Barre Syndrome (GBS) Report
  • Market Research Process
  • Market Research Methodology
  • Global Guillain-Barre Syndrome (GBS) Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Gender
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Market Sales By Geography (USD MN)
  • Supportive treatment Market Sales By Geography (USD MN)
  • Global Market Analysis By Type (USD MN)
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Sales By Geography (USD MN)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Sales By Geography (USD MN)
  • Miller Fisher Syndrome (MFS) Market Sales By Geography (USD MN)
  • Acute Motor Axonal Neuropathy (AMAN) Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Gender (USD MN)
  • Male Market Sales By Geography (USD MN)
  • Female Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Below 20 years Market Sales By Geography (USD MN)
  • 21-40 years Market Sales By Geography (USD MN)
  • 41-59 years Market Sales By Geography (USD MN)
  • 60 and above Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Rehabilitation Centers Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.